Meghan J. Mooradian

Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.

Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Clinical characterization of colitis arising from anti-PD-1 based therapy

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy